CAHQL:评估先天性肾上腺增生症健康相关生活质量的患者报告结局工具
研究按照FDA患者报告结局工具开发指南,开发并验证了针对16岁以上经典型先天性肾上腺增生症(CAH)患者的疾病特异性生活质量量表CAHQL。最终问卷含7个维度44个问题,内部一致性可接受(Cronbach's alpha ≥ 0.6),效度良好(r = -0.350 至 0.866)。CAHQL是首个经验证的CAH疾病特异性患者报告结局工具。
要点
- CAHQL含44个问题、7个维度,覆盖全面健康、肾上腺功能不全、糖皮质激素过量、躯体功能、心理与认知、社会功能、性功能。
- 内部一致性可接受(Cronbach's alpha ≥ 0.6),效度良好(r = -0.350 至 0.866)。
- CAHQL是首个经验证的CAH疾病特异性患者报告结局工具,可用于临床及评估新疗法疗效。
核心结论
- CAHQL是首个经验证的、可捕捉CAH疾病特异性健康相关生活质量结局的患者报告结局工具。
- 除预期用于临床环境外,该工具还可用于评估在研新疗法的疗效。
研究设计与样本
- 遵循FDA患者报告结局工具开发指南,先构建概念框架。
- 访谈12例16至68岁CAH患者和3名家长,并获取4名内分泌科专家的反馈,形成初步工具。
- 经6例患者认知访谈后对工具进行编辑。
- 69例16至75岁患者参与初步工具的验证。
主要发现
- 最终问卷含7个维度共44个问题:全面健康、肾上腺功能不全、糖皮质激素过量、躯体功能、心理与认知、社会功能、性功能。
- 内部一致性可接受(Cronbach's alpha ≥ 0.6)。
- 效度良好(r = -0.350 至 0.866)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Measuring health-related quality of life (HRQoL) is a crucial aspect of evaluating health care outcomes. Patients with congenital adrenal hyperplasia (CAH) often self-report deficiencies in HRQoL. OBJECTIVE: The aim of our study was to develop a disease-specific patient-reported outcome (PRO) instrument to evaluate the HRQoL of patients > 16 years old with classic CAH. METHODS: Following the FDA guidelines for developing PRO instruments, we developed a conceptual framework for the instrument. A preliminary instrument was created after interviewing a representative sample of 12 patients (aged 16 to 68 years) with CAH and 3 parents and obtaining expert feedback from 4 endocrinologists. The instrument was edited after cognitive interviews with 6 patients. Internal consistency of the instrument was evaluated using Cronbach's alpha. Validity was assessed by comparing the scores of our instrument with scores from widely used validated instruments for HRQoL and PRO not specific to CAH. RESULTS: Sixty-nine patients 16 to 75 years old participated in validating our preliminary instrument. The final questionnaire consists of 44 questions within 7 domains: General Health, Adrenal Insufficiency, Glucocorticoid Excess, Physical Functioning, Mental Health and Cognition, Social Functioning, and Sexual Functioning, with acceptable internal consistency (Chronbach's alpha ≥ .6) and validity (r = -0.350 to 0.866). CONCLUSION: CAHQL is the first validated PRO instrument to capture disease-specific HRQoL outcomes in CAH. In addition to its anticipated use in the clinical setting, the instrument could be used to assess the efficacy of novel treatments in development.
引用
- Flokas ME, Yang L, Middleton KR, et al. CAHQL: A Patient-Reported Outcome Instrument to Assess Health-Related Quality of Life in Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2025. PMID: 38706369. doi:10.1210/clinem/dgae309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。